Paper31325035
MicroRNAs: Key Players in Bladder Cancer.
Li Q and 7 others. Mol Diagn Ther, 2019. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. MicroRNAs: Key Players in Bladder Cancer. Papers, record 31325035. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31325035
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| MicroRNAs | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Exosomes | |
| Humans | |
| Molecular Diagnostic Techniques | |
| Neoplasm Grading | |
| Neoplasm Staging | |
| Prognosis | |
| RNA Interference |
Source PubMed
References203
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26905370 | Intravesical treatment of advanced urothelial bladder cancers with oncolytic HSV-1 co-regulated by differentially expressed microRNAs. | Gene Ther | 2016 | https://conductscience.org/library/papers/26905370 | PubMed |
| 2 | 30654976 | Measurement of Urinary Level of a Specific Competing endogenous RNA network (FOS and RCAN mRNA/ miR-324-5p, miR-4738-3p, /lncRNA miR-497-HG) Enables Diagnosis of Bladder Cancer. | Urol Oncol | 2019 | https://conductscience.org/library/papers/30654976 | PubMed |
| 3 | 27429046 | Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/27429046 | PubMed |
| 4 | 22361633 | Hedgehog pathway activation in human transitional cell carcinoma of the bladder. | Br J Cancer | 2012 | https://conductscience.org/library/papers/22361633 | PubMed |
| 5 | 26036261 | Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft. | Oncotarget | 2015 | https://conductscience.org/library/papers/26036261 | PubMed |
| 6 | 22265971 | MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. | FEBS Lett | 2012 | https://conductscience.org/library/papers/22265971 | PubMed |
| 7 | 28938585 | The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28938585 | PubMed |
| 8 | 25884322 | MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy. | BMC Cancer | 2015 | https://conductscience.org/library/papers/25884322 | PubMed |
| 9 | 19074842 | MicroRNAs and cancer: past, present, and potential future. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/19074842 | PubMed |
| 10 | 19116145 | Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. | Biochem Biophys Res Commun | 2009 | https://conductscience.org/library/papers/19116145 | PubMed |
| 11 | 11157775 | RNA interference is mediated by 21- and 22-nucleotide RNAs. | Genes Dev | 2001 | https://conductscience.org/library/papers/11157775 | PubMed |
| 12 | 23677384 | Decreased expression of miR-430 promotes the development of bladder cancer via the upregulation of CXCR7. | Mol Med Rep | 2013 | https://conductscience.org/library/papers/23677384 | PubMed |
| 13 | 23741253 | miR-96 regulates FOXO1-mediated cell apoptosis in bladder cancer. | Oncol Lett | 2012 | https://conductscience.org/library/papers/23741253 | PubMed |
| 14 | 25168920 | Urinary cell-free microRNA-106b as a novel biomarker for detection of bladder cancer. | Med Oncol | 2014 | https://conductscience.org/library/papers/25168920 | PubMed |
| 15 | 27099514 | Repression of the miR-93-enhanced sensitivity of bladder carcinoma to chemotherapy involves the regulation of LASS2. | Onco Targets Ther | 2016 | https://conductscience.org/library/papers/27099514 | PubMed |
| 16 | 24823697 | MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. | Br J Cancer | 2014 | https://conductscience.org/library/papers/24823697 | PubMed |
| 17 | 23863690 | Extracellular microRNAs in urologic malignancies: chances and challenges. | Int J Mol Sci | 2013 | https://conductscience.org/library/papers/23863690 | PubMed |
| 18 | 25498275 | Micro RNA expression and prognosis in low-grade non-invasive urothelial carcinoma. | Int Braz J Urol | 2014 | https://conductscience.org/library/papers/25498275 | PubMed |
| 19 | 27468885 | MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection. | Neoplasma | 2016 | https://conductscience.org/library/papers/27468885 | PubMed |
| 20 | 29363887 | Genome-wide identification of urinary cell-free microRNAs for non-invasive detection of bladder cancer. | J Cell Mol Med | 2018 | https://conductscience.org/library/papers/29363887 | PubMed |
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42793039 | Evaluation of Candidate Urinary microRNAs in Upper Tract Urothelial Carcinoma: A Prospective Multicenter Biomarker Study (JCOG1403A1). | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42793039 | PubMed |
| 41438986 | Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy. | Front Oncol | 2025 | https://conductscience.org/library/papers/41438986 | PubMed |
| 41252049 | Utilizing a novel mitochondrial-related gene signature for predicting the prognosis and immunological impact in bladder cancer. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41252049 | PubMed |
| 40937200 | miR-145-Mediated Tumor Suppression in Bladder Urothelial Carcinoma via Targeting the ADAMTS5/Wnt Signaling Axis. | Cureus | 2025 | https://conductscience.org/library/papers/40937200 | PubMed |
| 40124570 | 2'-Hydroxyflavanone inhibits bladder cancer cell proliferation and angiogenesis via regulating miR-99a-5p/mTOR signaling. | Am J Clin Exp Urol | 2025 | https://conductscience.org/library/papers/40124570 | PubMed |
| 39903549 | Innovative logic "AND" gate gene circuits for bladder cancer treatment: preclinical study. | Int J Surg | 2025 | https://conductscience.org/library/papers/39903549 | PubMed |
| 39041274 | ADAMTS16 Suppression by MicroRNA-25 Leads to Oncogenic Properties in Renal Cell Carcinoma. | Comb Chem High Throughput Screen | 2025 | https://conductscience.org/library/papers/39041274 | PubMed |
| 37715207 | Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs. | J Transl Med | 2023 | https://conductscience.org/library/papers/37715207 | PubMed |
| 37092087 | MicroRNA-186 suppresses cell proliferation and metastasis in bladder cancer. | Afr Health Sci | 2022 | https://conductscience.org/library/papers/37092087 | PubMed |
| 36499501 | miR-221-5p and miR-186-5p Are the Critical Bladder Cancer Derived Exosomal miRNAs in Natural Killer Cell Dysfunction. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36499501 | PubMed |
| 35403137 | Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models. | Cancer Diagn Progn | 2021 | https://conductscience.org/library/papers/35403137 | PubMed |
| 35004679 | Non-Coding RNA m6A Modification in Cancer: Mechanisms and Therapeutic Targets. | Front Cell Dev Biol | 2021 | https://conductscience.org/library/papers/35004679 | PubMed |
| 34988018 | Identification and Validation of Hub Genes Associated with Bladder Cancer by Integrated Bioinformatics and Experimental Assays. | Front Oncol | 2021 | https://conductscience.org/library/papers/34988018 | PubMed |
| 34659560 | MiR-25 regulates cell proliferation and metastasis in bladder urothelial carcinoma. | J Cancer | 2021 | https://conductscience.org/library/papers/34659560 | PubMed |
| 33997007 | Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis. | Biomed Res Int | 2021 | https://conductscience.org/library/papers/33997007 | PubMed |
| 33973417 | Exosomes in bladder cancer: novel biomarkers and targets. | J Zhejiang Univ Sci B | 2021 | https://conductscience.org/library/papers/33973417 | PubMed |
| 33846791 | Propofol modulates the proliferation, invasion and migration of bladder cancer cells through the miR‑145‑5p/TOP2A axis. | Mol Med Rep | 2021 | https://conductscience.org/library/papers/33846791 | PubMed |
| 33833571 | circCEP128 Knockdown Suppresses Bladder Cancer Progression via Regulating microRNA-515-5p/SDC1 Axis. | Cancer Manag Res | 2021 | https://conductscience.org/library/papers/33833571 | PubMed |
| 33312391 | Clinical effects and molecular mechanisms of lncRNA MNX1-AS1 in malignant tumors. | Am J Transl Res | 2020 | https://conductscience.org/library/papers/33312391 | PubMed |
| 33221743 | DNMT3B silencing suppresses migration and invasion by epigenetically promoting miR-34a in bladder cancer. | Aging (Albany NY) | 2020 | https://conductscience.org/library/papers/33221743 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31325035
GET https://conductscience.org/api/papers/v1/31325035/references?page=2